Why Moderna's mFlusiva flu shot could quietly change winter vaccinations

Reviewed: ad hoc news Lifestyle & Consumer desk. Edited and checked on 2026-06-19, 03:14. Details in the imprint.

With the mFlusiva flu vaccine, Moderna wants to bring the familiar sting in the upper arm into the mRNA age, just as people start layering up for winter. The shot is designed for adults 50 and over and promises strong protection in one quick jab.

What mFlusiva is aiming for

mFlusiva is Moderna's investigational seasonal flu vaccine built on the same mRNA platform that made its Covid shot widely known. It is targeted at adults aged 50 and above and is under FDA review as a protection against influenza in this group.

The vaccine, also known by the development code mRNA-1010, is designed to cover multiple influenza strains in a single shot. The idea is simple in everyday life: one brisk visit to the clinic before flu season, then walk out with updated protection.

How the data looks in practice

In a large study with around 40,000 participants aged 50 and over, mFlusiva reduced flu cases by roughly 27 percent compared with a commonly used comparator vaccine. That sounds modest, but for public health it can mean thousands fewer infections and hospital visits.

The FDA's own review found no major safety concerns in the data so far, which is crucial for older patients who often already swallow a handful of pills every morning. Reactogenicity - the typical soreness, fatigue, mild fever - appears broadly in line with other modern flu shots according to the advisory material.

What the FDA panel just decided

On 18 June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of Moderna's mRNA-1010 vaccine outweigh the risks for adults aged 50 to 64. The same 9-0 backing was given for people aged 65 and older, a key high-risk group.

These votes are not the final green light, but they carry weight. They signal to clinicians and health insurers that regulators see a convincing benefit-risk profile and pave the way for an approval decision ahead of upcoming flu seasons.

How it could feel in everyday use

For a patient, mFlusiva should feel familiar: a quick alcohol swab on the upper arm, a short sting, maybe a dull ache that flares when you pull on a coat later. The novelty is under the skin, not in the experience at the doctor's office.

The mRNA approach is meant to allow faster updates when the circulating flu strains shift. For people who already lined up for mRNA Covid boosters, the concept is almost routine by now, even if the target virus is different.

Where questions still remain

Regulators have flagged that there is still limited data in very frail older adults and people with severely weakened immune systems. In practice, these are often the nursing home residents and multi-morbid patients who worry most about flu complications.

There is also the performance question: a 27 percent reduction versus a standard vaccine is a clear edge, but not a knockout. How strongly doctors switch their ordering habits will depend on real-world experience and on how the final label and recommendations are written.

Availability, markets, pricing

mFlusiva is currently under regulatory review in the United States, the European Union, Canada and Australia, with further submissions planned during 2026. If the FDA grants approval by its target date in early August, supply for the US market could follow relatively quickly for the next flu season.

Official list prices are not yet public, but positioning suggests a premium over standard inactivated flu vaccines, more in line with other high-dose or adjuvanted products. For patients in the US, insurer coverage and Medicare decisions will be crucial for whether the shot feels accessible or expensive at the pharmacy counter.

What it means for Moderna and the share

For Moderna, mFlusiva is meant to prove that mRNA vaccines can be more than a Covid story and become a stable, seasonal business pillar. A solid flu franchise could smooth revenue swings and support further pipeline work in RSV, combined respiratory shots and beyond.

Shares of Moderna (US60770K1079) recently moved higher on the back of the advisory committee's endorsement for the flu vaccine on Nasdaq in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.